Curcumin inhibits carcinogen and nicotine-induced mammalian target of rapamycin pathway activation in head and neck squamous cell carcinoma
Cancer Prev Res. 2010;3(12):1586-95
|Despite of decrease in the prevalence of cigarette smoking, in the USA, 30% of cancer deaths are due to cigarette smoking and 90-95% of diagnosed head and neck squamous cell carcinoma (HNSCC) are tobacco-related with ~40,000 new cases, 13,000 U.S. deaths and 500,000 new cases worldwide. It has been found that cigarette smokers are 3 times more likely to develop smoking-related second primary tumors than non-smokers. Hence, there is urgent need for chemopreventive agents.|
Tobacco use at HNSCC diagnosis is a recognized risk factor for second primary tumors (SPTs), and current smokers are 3 times more likely than never-smokers to develop smoking-related SPT (6), indicating a need for chemopreventive agents among tobacco users.
One promising agent is Curcumin, which has been implicated as a powerful therapeutic agent in several human cancers, as it has the ability to block tumor initiation and progression in several types of cancers.
To examine the effects of Curcumin on HNSCC growth in a variety of HNSCC cell lines, xenograft model and in a carcinogen-induced survival study.
Results and Discussion:
Curcumin effectively inhibited the adverse effects of nicotine by blocking nicotine-induced activation of the AKT/MTOR pathway in HNSCC, in turn retarding cell migration, suggesting that Curcumin may be useful as an oral chemopreventive agent.